The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer

Pancreatic Adenocarcinoma Clinical Trial

Official title:

The HELPP Score: A Pretreatment Prognostic Score to Predict Survival and Patterns of Recurrence in Localized Non-Metastatic Pancreatic Cancer - a Multicenter Prospective Validation Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05752812
• Other study ID #: MUVienna HELPP
• Status: Recruiting
• Start date: March 1, 2023
• Est. completion date: November 2026

Study information

• Verified date: October 2023
• Source: Medical University of Vienna
• Contact: Carl Leonhardt, MD MBA
• Phone: +43140400
• Email: carl-stephan.leonhardt[@]meduniwien.ac.at
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to validate a pretreatment prognostic score (Heidelberg Prognostic Pancreatic Cancer Score - HELPP) in patients with pancreatic ductal adenocarcinoma.

The main questions it aims to answer are:

• Is the HELPP score able to predict median overall survival in a prospective multi-institutional cohort of patients with pretherapeutic localized non-metastatic pancreatic cancer?

• Is the HELPP score able to predict median recurrence-free survival and patterns of recurrence after resection of pancreatic cancer?

Description:

Accurate pretreatment staging and subsequent prediction of prognosis in pancreatic ductal adenocarcinoma (PDAC) is challenging due to subclinical micrometastasis as well as variations in tumor biology. Moreover, patients with non-metastasized localized PDAC are increasingly treated with neoadjuvant chemotherapy prior to resection.

The investigators recently developed a preoperative prognostic score to predict postoperative outcomes based on routine laboratory biomarkers and the American Society of Anesthesiologists (ASA) score, the HELPP score (Heidelberg Prognostic Pancreatic Cancer Score). Based on a large retrospective analysis of 1197 patients and an external validation cohort the HELPP score was able stratify patients based on expected survival only utilizing routinely available preoperative data. However, prospective validation is currently lacking.

This multi-site prospective observational study aims to prospectively validate the HELPP score in the clinical scenarios described above. Additionally, it aims to investigate its utility regarding median recurrence-free survival and patterns of recurrence. The study includes all consecutive patients with PDAC undergoing exploration (without or without neoadjuvant treatment) with the aim of resection within a timeframe of 12 months (all-comers concept, snapshot study).

The parameters on which the score is based on are routinely available to hospitals worldwide. Simplicity of the grading system facilitates implementation in daily clinical practice. This score could potentially help tailor treatments, aid in patient stratification in clinical trials, and provide new insights into tumor biology.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1500
• Est. completion date: November 2026
• Est. primary completion date: May 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• =18 years old

• fit to undergo elective pancreatic resection or palliative therapy

• localized non-metastatic pancreatic ductal adenocarcinoma

• informed consent provided

Exclusion Criteria:

• patients with a diagnosis other than pancreatic ductal adenocarcinoma on histopathology

• missing informed consent

• missing mandatory pretreatment laboratory values

• missing mandatory pretreatment clinicopathologic data

• patients receiving surgery for peripancreatic cancer

• incomplete follow-up records

• follow-up < 24 months

• pregnancy

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreatic Adenocarcinoma

Locations

Country	Name	City	State
Austria	Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

References & Publications (1)

Hank T, Hinz U, Reiner T, Malleo G, Konig AK, Maggino L, Marchegiani G, Kaiser J, Paiella S, Binco A, Salvia R, Hackert T, Bassi C, Buchler MW, Strobel O. A Pretreatment Prognostic Score to Stratify Survival in Pancreatic Cancer. Ann Surg. 2022 Dec 1;276(6):e914-e922. doi: 10.1097/SLA.0000000000004845. Epub 2021 Mar 4. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Median overall survival	Median overall survival from the time of diagnosis with pancreatic ductal adenocarcinoma to time of death due to any cause.	Date of diagnosis to date of death; assessed up to 60 months
Secondary	Recurrence-free survival	Median recurrence-free survival from the date of potentially curative pancreatic surgery for pancreatic ductal adenocarcinoma until detection of the first evidence of recurrent disease either based on cross-sectional imaging or cytology/histology.	Date of surgery to date of the first evidence of recurrent disease; assessed up to 60 months
Secondary	Patterns of recurrence	Patterns of recurrence either based on cross-sectional imaging or cytology/histology after potentially curative pancreatic surgery of pancreatic ductal adenocarcinoma. The location of recurrence will be defined based on the first site of recurrence. Only the first site of recurrence will be considered.	Date of surgery to date of the first evidence of recurrent disease; assessed up to 60 months